Page 172 - Read Online

Page 536 Belizario et al. Cancer Drug Resist 2019;2:527-38 I http://dx.doi.org/10.20517/cdr.2018.009

DECLARATIONS
Acknowledgments
Maria Mitzi Brentani, Fiorita Mundim, Alda Wakamatsu, Venancio AF Alves (University of São Paulo
School of Medicine Medicine) and Dr Victor Piana Andrade e Fernando Soares (AC Carmargo Cancer
Center) for their help and fruitful discussions.

Author’s contribution
Study conception: Belizario JE, Loggulo AF
Selection and critical review of the papers and manuscript preparation: Belizario JE, Loggulo AF
Read and approved the final manuscript: Belizario JE, Loggulo AF

Availability of data and materials
Not applicable.

Financial support and sponsorship
JEB is supported by fellowship from “Conselho Nacional de Desenvolvimento Científico e Tecnológico”
(CNPq proc 486048/2011; 312206/2016-0).

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Belizario JE. Cancer risks linked to the bad luck hypothesis and epigenomic mutational signatures. Epigenomes 2018;2:13.
2. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA et al. Discovery and saturation analysis of cancer genes across 21
tumour types. Nature 2014;505:495-501.
3. Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids
Res 2018;46:D956-63.
4. Kim YA, Cho DY, Przytycka TM. Understanding genotype - phenotype effects in cancer via network approaches. PLoS Comput Biol
2016;12:e1004747.
5. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. The Cancer Cell Line Encyclopedia enables predictive
modeling of anticancer drug sensitivity. Nature 2012;483:603-7.
6. Garnett MJ, Edelman J, Heidorn SJ, Greenman CD, Dastur A, et al. Systematic identification of genomic markers of drug sensitivity
in cancer cells. Nature 2012;483:570-5.
7. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat
Biotechnol 2015;33:306-12.
8. Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, et al. Large-scale profiling of kinase dependencies in cancer cell lines.
Cell Rep 2016;15:14:2490-501.
9. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2008;25:30-8.
10. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell
2015;27:15-26.
11. Belizario JE, Sangiuliano BA, Perez-Sosa M, Neyra JM, Moreira DF. Using pharmacogenomic databases for discovering patient-
target genes and small molecule candidates to cancer therapy. Front Pharmacol 2016;7:312.
12. Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat